Why the study?
Does genotype-guided dosing of warfarin improve the percentage of time in the therapeutic INR range in patients initiating warfarin therapy?
Does genotype-guided dosing of warfarin improve the percentage of time in the therapeutic INR range in patients initiating warfarin therapy?
Genotype-guided dosing of warfarin improves the time in therapeutic INR range during therapy initiation compared to standard dosing.
No takes yet. Share an insight, caveat, or question.
Supports genotype-guided warfarin dosing at initiation; confirms RCT benefit for TTR over standard dosing.
Pirmohamed et al. (2013) studied this question.
Synapse has enriched 3 closely related papers on similar clinical questions. Consider them for comparative context: